



Trimethylaminuria (TMAU)

George Preti, Ph.D.

Monell Chemical Senses Center

Department of Dermatology, Perelman School of
Medicine, University of Pennsylvania

Outline

- 1. Background: TMAU as disease entity, the choline challenge test for diagnosis*
- 2. Evaluation of individuals with malodor problems*
- 3. Genetics of TMAU*

Rare Diseases by the Numbers

RARE DISEASES BY THE NUMBERS


A disease is defined as orphan in the U.S. when it affects fewer than

200,000
people

There are approximately

7,000

types of rare diseases and disorders



95%

of rare diseases have no FDA-approved drug treatment

80%

of rare diseases are genetic in origin

Approximately
50%

of those affected by rare diseases are children

30%

of children with a rare disease will not live to see their fifth birthday

8: Average number of physician visits before diagnosis

3: Average number of misdiagnoses

7+ years: Average time until diagnosis

SOURCES: National Organization for Rare Diseases, Global Genes Project

Most Normal Human Body & Oral Odors Formed By Interactions of Skin Gland Secretions and Microorganisms



- **Scalp/Hair**
- **Mouth Breath**
- **Cerumen**
- **Axillae/Underarms**
- **Chest**
- **Genital/Vaginal**
- **Feet**
- **Skin/Hands**

Prior to the 20th century and the wide-spread use of scented soaps and consumer products, it was more readily apparent that humans emit a variety of volatile odorous metabolites.

Lack of knowledge among health-care professionals surrounding TMAU may impede diagnosis*

- Most health professional training curricula (medical, nursing, etc.) fail to include the symptoms and causes of TMAU!
- Episodic intensity of odor often confuses the diagnosis.
- Inheritance of TMAU is often unclear to health providers, and genetic tests often are inconclusive: they may not demonstrate phenotype
- Don't go to the "doctor down the street;" go to a major teaching hospital/medical center: genetic and metabolic disease specialists

* Thanks to Dr. P.V. Fennessey

Lack of knowledge among health-care professionals surrounding TMAU may Impede diagnosis*

- Information is available
 - The Internet
 - Patient support groups
 - Other rare disease info on TV and the Web

Without these sources, many TMAU patients would still be in the dark about this genetic disease!

*Thanks to Dr. P.V. Fennessey

TMAU: some history*

- **1842 and 1858**
 - Two reports of TMAU-like disease (*Lancet*)
- **1970**
 - First clinical description: Humbert et al., in Denver (*Lancet*)
- **1970-1985**
 - Reports of isolated and sporadic cases
 - Data suggest diet plays an important role in the disease
- **1980-2000**
 - Genetic studies of N-oxidation (FMO3) and other cofactors
- **1995 to present**
 - Systematic recognition of this rare genetic disease

*Thanks to Dr. P.V. Fennessey

Measurement of Urinary TMA Concentration*

1980 - 1984: Total TMA (mg/mg creatinine)
(concentration depends on diet)

1984 - present: Total TMA before and after ingestion of choline test load

Ratio: $(\text{TMAO} / \text{TMA}) \times 100\%$

Normal TMAO > 95%
(ratio independent of diet)

Currently we provide: TMA & TMAO conc. as micromoles/millimole of creatinine as well as %TMAO.

University of Colorado, Dept. of Pediatrics, Biochemical Genetics Laboratory (www.DenverGenetics.org)

*Thanks to Dr. P.V. Fennessey

Causes of Variability in TMA Odor Intensity*

- Estimated production of TMA from turnover of intrinsic biomolecules:
 - Micrograms (0.001 mg)
- Estimated production of TMA from action of gut bacteria on natural products in the diet
 - Milligrams (>1.0 mg)
- **Difference of >1000x (depending on diet)**

*Thanks to Dr. P.V. Fennessey

Monell Patient Characteristics

1. ~1985-1995: many referred by physician or dentist
2. Internet: many now self-referred
3. Patients mostly from the U.S., but also from Canada, Honduras, Venezuela and the U.K.
4. Many have been to ≥ 4 clinical and/or dental specialists
5. All patients had multi-step exam involving both analytical and sensory techniques: the critical part is a choline challenge test to determine the diagnosis of TMAU.
6. Most of our in-house in vivo evaluations of patients were done between 1988 – 2008 (~ 350 individuals).
7. Starting around 2003 we began using a home testing kit; now almost all testing done this way

Large Undiagnosed Population of Individuals with Trimethylaminuria

- Diagnosed via Choline Challenge Test (CCT; Tjoa and Fennessey, Anal. Biochem.197:77-82, 1991)
- Trimethylamine (TMA) is a gas at body temperature and has a strong, pungent, offensive, fish-odor; at low concentrations it may be perceived as “foul” or “unpleasant” Reported to be found in all body fluids
- “Fish odor syndrome” should not be used. Only ~10% of our TMAU-positive individuals have this presentation.
- Symptoms are sporadic and may escape notice due to low choline intake or specific anosmia in the clinician (rare).

Trimethylaminuria Patients at Monell Center

- >350 individuals
- 111 (~ 32%) diagnosed with some form of TMAU (Dr. Reed will elaborate further)
- Average age of our TMAU-affected population is 43.6 years (range 3 to 79 years)

Patient Self-reports of Symptoms

Reasons for seeking help






Figure 1. Presenting symptoms of TMAU-positive patients

3x More Women Than Men Are TMAU Positive

Many Are African-American



Females' Ability to Metabolize TMA Depends on where they are in their Menstrual Cycle



In both genders, variability in TMA Odor intensity can be linked to rate of production*

TMA appearance after a 5 g oral choline load (adult):


<u>0 - 8 hours</u>	23%	(rapid passage through gut)
<u>8 - 16 hours</u>	55%	(slow passage through gut)
<u>16 - 24 hours</u>	22%	(poor passage through gut)

Suggestion that bacteria in colon is cause of peak production

- Supported by literature reports/case studies of TMA suppression by antibiotics
- Also, how you perform the choline challenge is important
- As previous slide showed, for pre-menopausal females, when you test is important

* Adapted from Tjoa and Fennessey, 1991

Choline Utilization (Cut) Gene Cluster



Looking ahead: can these be influenced?

- Proportion of gut bacteria with *Cut* enzymes
- Small molecule inhibitors of *Cut* enzymes
- Are these bacteria found elsewhere...? Most likely

TMAU: Non-Related Complications

1. Syndromes such as Prader-Willi and Noonan's
2. Skin Rashes
3. Seizures
4. Hypertension (severe, labile, moderate)
5. Psychiatric dysfunction...impaired metabolism of
6. N- and S- containing compounds
7. Depression
8. Sarcoidosis
9. IBS and other lower GI problems (??)
10. Females: recurring fishy vaginal odor not related to TMAU, e.g.,
cut enzyme-containing bacteria problem
11. Present in bacterial plaque on the tongue?

Most patients appear to lead normal lives & work at a variety of professions

Main problem: Psycho-social problems caused by odor production/symptoms.

Tied to individual personality

Summary

- Our results demonstrate the necessity to screen for TMAU with an objective, analytical test and not rely upon anyone's olfactory abilities.
 - Only ~ 10% of patients with TMAU have had a fish-like or malodor during their exam
 - Patients may not be aware of when odor is present or the intensity of their own odor.
 - In our referred patient population, most patients have had a similar history. Many do not smell badly at all (organoleptic evaluation of breath, axillae, clothing items).
 - Very few patients have high levels of odor-producing axillary bacteria (rel. to "normal") or much axillary odor
 - Amelioration of symptoms:
 - short term antibiotics, osmotic laxatives
 - longer term choline & salt water fish restriction, OTC supplements.
- For many "nothing works" without positive reinforcement: use an odor buddy

Summary...continued

- Both TMAU and non-TMAU patients may have bad breath caused by volatile sulfur compounds
 - 57% of TMAU-positive patients
 - 60% of non-TMAU patients
- Female patients
 - either more affected by TMAU
 - or present in greater numbers to a clinic for relief of symptoms
 - many are African-American
- Decreased FMO3 efficiency due to complications, e.g. viral infections/ drug intake.
- Funding needed for
 - follow-up
 - in-depth study of symptoms vs. treatment regimes.
- Etiology/Genetics/Other odor-producing genetic disorders ??
- My question to the audience: why are so many test kits requested but only 40-60% returned?